2024
November 20, 2024
New Association Launches to Expand Patient Access to Psychedelic Medicines
psychedelicsRX.org
June 18, 2024
Ceruvia Founder and CEO, Carey Turnbull, Featured in New Book “Psychedelic Outlaws”
PR Newswire
2023
January 23, 2023
Psilocybin sex-dependently reduces alcohol consumption in mice
Frontiers in Pharmacology
January 19, 2023
Ceruvia Lifesciences Begins Dosing Volunteers In Research On Non Hallucinogenic LSD Compound
Bezinga
January 17, 2023
Ceruvia Lifesciences Announces First Participant Dosed in BOL-148 Phase 1 Clinical Trial
CISION PR Newswire
2022
December 1, 2022
Advocacy for Medicinal Use of Controlled Substances
Bob Wold; Eileen Brewer; and Kevin Lenaburg, Practical Neurology
November 17, 2022
Changing Lives With Psychedelics: How Connecticut Researchers are Using Magic Mushrooms to Help People Overcome Depression, OCD
November 2, 2022
Ceruvia Lifesciences Appoints Stephen Hurst and David Steinberg to its Board of Directors
October 27, 2022
Ceruvia Founder and CEO, Carey Turnbull, to Appear at Wonderland Miami
October 14, 2022
Ceruvia Collaborators, Dr. Christopher Pittenger and Dr. Emmanuelle Schindler, to Present at Horizons New York Psychedelic Research Forum
October 13, 2022
Ceruvia Founder and CEO, Carey Turnbull, to Appear at Horizons New York Psychedelic Business Forum
October 6, 2022
Ceruvia Founder and CEO, Carey Turnbull, to Appear at Horizons New York Psychedelic Business Forum
June 27, 2022
Ceruvia Lifesciences Receives FDA Investigational New Drug Approval for Psilocybin Obsessive-Compulsive Disorder Program Phase 2 Trial
Ceruvia Lifesciences Press Release
June 21, 2022
Ceruvia Lifesciences Submits FDA Investigational New Drug Application for NYPRG-101 Migraine Prevention Program
Ceruvia Lifesciences Press Release
June 3, 2022
Free LSD, Canadian government decriminalizes certain drugs in B.C., and psychedelic-assisted therapy
The Microdose, Jane C. Hu
May 31, 2022
Ceruvia Lifesciences to Supply LSD to Qualified Researchers at No Cost
Ceruvia Lifesciences Press Release
May 24, 2022
Ceruvia Lifesciences Submits FDA Investigational New Drug Application for Psilocybin Obsessive-Compulsive Disorder Program
Ceruvia Lifesciences Press Release
May 24, 2022
Ceruvia Lifesciences on the mechanism of migraine and prescription psychedelic medicines
The Psychedelics Newsletter, Issue 82
April 8, 2022
Funders at Johns Hopkins Shape The Future of Psychedelic Research
Lucid News, Marc Gunther
March 10, 2022
Johns Hopkins, Yale, and NYU are teaming up to tackle a key bottleneck that will arise as psychedelics come to market
Business Insider, Yeji Jesse Lee
March 10, 2022
Grant Supports Development of Training for Psychiatrists in Psychedelic Medicine
Yale Medicine, Christopher Gardner
February 20, 2022
Psychoactive ingredient in ‘magic’ mushrooms may treat depression for much longer than traditional antidepressants when combined with therapy
Business Insider, Dr. Catherine Schuster-Bruce
2021
November 8-9, 2021
Microdose Presents: Wonderland : Miami
From November 8-9 at the Adrienne Arsht Center for the Performing Arts in Miami, Florida, we will gather together the top experts,
researchers, and industry leaders to discuss the latest developments and innovations in the psychedelics industry.
October 29–November 1, 2021
Psych Congress – San Antonio, TX
Psych Congress is more than just premier psychopharmacology education. It also serves as a valuable forum for U.S.-based
mental health professionals to connect with, learn from, and share in the joy and challenges of their work.
July 30, 2021
Psilocybin in ‘magic mushrooms’ helping depression, OCD, research shows
The Stamford Advocate. Ed Stannard
July 8, 2021
2021 IOCDF Research Symposium
This exclusive event for researchers will consist of a live, interactive program that includes a series of high-level talks and two live poster sessions.
The symposium will take place via Zoom on Thursday, July 8th from 10:30am–4:45pm US Eastern Time (UTC-04:00)
April 3, 2021
A new treatment may halt cluster headaches. But some say psychedelic drugs are the real answer
Washington Post. Katherine Ellison
March 22, 2021
NYU Raises $10M For Psychedelic Research and Training Center
LUCID NEWS. Colin Newton
March 12, 2021
Wealthy donors are fueling a psychedelics renaissance as
universities vie for funding to study ‘magic mushrooms’ and MDMA
BUSINESS INSIDER. Yeji Jesse Lee
February 25, 2021
NYU Establishes Center For Psychedelic Medicine With $10 Million From MindMed, Philanthropists
Forbes. Amanda Siebert
2020
December 2, 2020
Psychedelics in Psychiatry—Keeping the Renaissance From Going Off the Rails
David B. Yaden, PhD, Mary E. Yaden, MD, Roland R. Griffiths, PhD
February 17, 2020
Business gets ready to trip: How psychedelic drugs may revolutionize mental health care
FORTUNE. Jeffrey M. O’Brien
2015
October 31, 2015
The Trip Treatment: Research into psychedelics, shut down for decades, is now yielding exciting results
The New Yorker. Michael Pollan
2019
2018
2023
January 23, 2023
Psilocybin sex-dependently reduces alcohol consumption in mice
Frontiers in Pharmacology
January 19, 2023
Ceruvia Lifesciences Begins Dosing Volunteers In Research On Non Hallucinogenic LSD Compound
Bezinga
January 17, 2023
Ceruvia Lifesciences Announces First Participant Dosed in BOL-148 Phase 1 Clinical Trial
CISION PR Newswire
2022
December 1, 2022
Advocacy for Medicinal Use of Controlled Substances
Bob Wold; Eileen Brewer; and Kevin Lenaburg, Practical Neurology
November 17, 2022
Changing Lives With Psychedelics: How Connecticut Researchers are Using Magic Mushrooms to Help People Overcome Depression, OCD
November 2, 2022
Ceruvia Lifesciences Appoints Stephen Hurst and David Steinberg to its Board of Directors
October 27, 2022
Ceruvia Founder and CEO, Carey Turnbull, to Appear at Wonderland Miami
October 14, 2022
Ceruvia Collaborators, Dr. Christopher Pittenger and Dr. Emmanuelle Schindler, to Present at Horizons New York Psychedelic Research Forum
October 13, 2022
Ceruvia Founder and CEO, Carey Turnbull, to Appear at Horizons New York Psychedelic Business Forum
October 6, 2022
Ceruvia Founder and CEO, Carey Turnbull, to Appear at Horizons New York Psychedelic Business Forum
June 27, 2022
Ceruvia Lifesciences Receives FDA Investigational New Drug Approval for Psilocybin Obsessive-Compulsive Disorder Program Phase 2 Trial
Ceruvia Lifesciences Press Release
June 21, 2022
Ceruvia Lifesciences Submits FDA Investigational New Drug Application for NYPRG-101 Migraine Prevention Program
Ceruvia Lifesciences Press Release
June 3, 2022
Free LSD, Canadian government decriminalizes certain drugs in B.C., and psychedelic-assisted therapy
The Microdose, Jane C. Hu
May 31, 2022
Ceruvia Lifesciences to Supply LSD to Qualified Researchers at No Cost
Ceruvia Lifesciences Press Release
May 24, 2022
Ceruvia Lifesciences Submits FDA Investigational New Drug Application for Psilocybin Obsessive-Compulsive Disorder Program
Ceruvia Lifesciences Press Release
May 24, 2022
Ceruvia Lifesciences on the mechanism of migraine and prescription psychedelic medicines
The Psychedelics Newsletter, Issue 82
April 8, 2022
Funders at Johns Hopkins Shape The Future of Psychedelic Research
Lucid News, Marc Gunther
March 10, 2022
Johns Hopkins, Yale, and NYU are teaming up to tackle a key bottleneck that will arise as psychedelics come to market
Business Insider, Yeji Jesse Lee
March 10, 2022
Grant Supports Development of Training for Psychiatrists in Psychedelic Medicine
Yale Medicine, Christopher Gardner
February 20, 2022
Psychoactive ingredient in ‘magic’ mushrooms may treat depression for much longer than traditional antidepressants when combined with therapy
Business Insider, Dr. Catherine Schuster-Bruce
2021
November 8-9, 2021
Microdose Presents: Wonderland : Miami
From November 8-9 at the Adrienne Arsht Center for the Performing Arts in Miami, Florida, we will gather together the top experts,
researchers, and industry leaders to discuss the latest developments and innovations in the psychedelics industry.
October 29–November 1, 2021
Psych Congress – San Antonio, TX
Psych Congress is more than just premier psychopharmacology education. It also serves as a valuable forum for U.S.-based
mental health professionals to connect with, learn from, and share in the joy and challenges of their work.
July 30, 2021
Psilocybin in ‘magic mushrooms’ helping depression, OCD, research shows
The Stamford Advocate. Ed Stannard
July 8, 2021
2021 IOCDF Research Symposium
This exclusive event for researchers will consist of a live, interactive program that includes a series of high-level talks and two live poster sessions.
The symposium will take place via Zoom on Thursday, July 8th from 10:30am–4:45pm US Eastern Time (UTC-04:00)
April 3, 2021
A new treatment may halt cluster headaches. But some say psychedelic drugs are the real answer
Washington Post. Katherine Ellison
March 22, 2021
NYU Raises $10M For Psychedelic Research and Training Center
LUCID NEWS. Colin Newton
March 12, 2021
Wealthy donors are fueling a psychedelics renaissance as
universities vie for funding to study ‘magic mushrooms’ and MDMA
BUSINESS INSIDER. Yeji Jesse Lee
February 25, 2021
NYU Establishes Center For Psychedelic Medicine With $10 Million From MindMed, Philanthropists
Forbes. Amanda Siebert
2020
December 2, 2020
Psychedelics in Psychiatry—Keeping the Renaissance From Going Off the Rails
David B. Yaden, PhD, Mary E. Yaden, MD, Roland R. Griffiths, PhD
February 17, 2020
Business gets ready to trip: How psychedelic drugs may revolutionize mental health care
FORTUNE. Jeffrey M. O’Brien
2015
October 31, 2015
The Trip Treatment: Research into psychedelics, shut down for decades, is now yielding exciting results
The New Yorker. Michael Pollan
2019
2018
CONTACT CERUVIA
Stay informed of Ceruvia news and research